{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:05:36Z","timestamp":1792253136037,"version":"4.4.0"},"reference-count":217,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":34,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.neurot.2026.e00857","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:33:13Z","timestamp":1772022793000},"page":"e00857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel therapeutics in autism spectrum disorder"],"prefix":"10.1016","volume":"23","author":[{"family":"Sara Daniella Kevelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Elmaghraby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallie","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Gorenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Bain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary Michael","family":"Grinspan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernie","family":"Pedapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Veenstra-VanderWeele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankhuree","family":"Vandana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2026.e00857_bib1","first-page":"111","article-title":"The global epidemiology and health burden of the autism spectrum: findings from the global burden of disease study","author":"Santomauro","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00857_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss7402a1","article-title":"Prevalence and early identification of autism spectrum disorder among children aged 4 and 8 years \u2014 autism and developmental disabilities monitoring network, 16 sites, United States, 2022","volume":"2025","author":"Shaw","year":"2025","journal-title":"MMWR Surveill Summ"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00857_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF02105365","article-title":"A behavior modification approach to the treatment of autistic children","volume":"4","author":"Lovaas","year":"1974","journal-title":"J Autism Child Schizophr [Internet]"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00857_bib4","article-title":"Could you give me the blue brick? LEGO((R))-based therapy as a social development program for children with autism spectrum disorder: a systematic review","volume":"11","author":"Narzisi","year":"2021","journal-title":"Brain Sci [Internet]"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00857_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10803-004-2550-0","article-title":"Use of LEGO as a therapeutic medium for improving social competence","volume":"34","author":"LeGoff","year":"2004","journal-title":"J Autism Dev Disord [Internet]"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00857_bib6","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1007\/s10803-021-05137-y","article-title":"Concerns about ABA-based intervention: an evaluation and recommendations","volume":"52","author":"Leaf","year":"2022","journal-title":"J Autism Dev Disord [Internet]"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00857_bib7","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1007\/s10803-021-05316-x","article-title":"Neurodiversity and autism intervention: reconciling perspectives through a naturalistic developmental behavioral intervention framework","volume":"52","author":"Schuck","year":"2022","journal-title":"J Autism Dev Disord [Internet]"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00857_bib8","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s10803-015-2407-8","article-title":"Naturalistic developmental behavioral interventions: empirically validated treatments for autism spectrum disorder","volume":"45","author":"Schreibman","year":"2015","journal-title":"J Autism Dev Disord [Internet]"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00857_bib9","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jaac.2012.08.003","article-title":"Effects of a brief early start Denver model (ESDM)-based parent intervention on toddlers at risk for autism spectrum disorders: a randomized controlled trial","volume":"51","author":"Rogers","year":"2012","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00857_bib10","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jaac.2019.01.004","article-title":"A multisite randomized controlled two-phase trial of the early start Denver model compared to treatment as usual","volume":"58","author":"Rogers","year":"2019","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00857_bib11","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1007\/s10803-013-1840-9","article-title":"Initial efficacy of project ImPACT: a parent-mediated social communication intervention for young children with ASD","volume":"43","author":"Ingersoll","year":"2013","journal-title":"J Autism Dev Disord [Internet]"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib12","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1542\/peds.2013-3229","article-title":"Caregiver-mediated intervention for low-resourced preschoolers with autism: an RCT","volume":"134","author":"Kasari","year":"2014","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib13","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1044\/2022_AJSLP-21-00239","article-title":"Cultural adaptations to parent-mediated autism spectrum disorder interventions for Latin American families: a scoping review","volume":"31","author":"DuBay","year":"2022","journal-title":"Am J Speech Lang Pathol [Internet]"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00857_bib14","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1007\/s10803-022-05592-1","article-title":"From clinic room to zoom: delivery of an evidence-based, parent-mediated intervention in the community before and during the pandemic","volume":"52","author":"Graucher","year":"2022","journal-title":"J Autism Dev Disord [Internet]"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib15","article-title":"Parent mediated intervention programmes for children and adolescents with neurodevelopmental disorders in south Asia: a systematic review","volume":"16","author":"Koly","year":"2021","journal-title":"PLoS One [Internet]"},{"key":"10.1016\/j.neurot.2026.e00857_bib16","article-title":"Assessing the satisfaction and acceptability of an online parent coaching intervention: a mixed-methods approach","volume":"13","author":"Qu","year":"2022","journal-title":"Front Psychol [Internet]"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00857_bib17","article-title":"Parent-mediated intervention training delivered remotely for children with autism spectrum disorder living outside of urban areas: systematic review","volume":"19","author":"Parsons","year":"2017","journal-title":"J Med Internet Res [Internet]"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib18","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10567-021-00358-0","article-title":"Telehealth and autism prior to and in the age of COVID-19: a systematic and critical review of the last decade","volume":"24","author":"Ellison","year":"2021","journal-title":"Clin Child Fam Psychol Rev [Internet]"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10803-020-04439-x","article-title":"A pilot study comparing tele-therapy and In-Person therapy: perspectives from parent-mediated intervention for children with autism spectrum disorders","volume":"51","author":"Hao","year":"2021","journal-title":"J Autism Dev Disord [Internet]"},{"key":"10.1016\/j.neurot.2026.e00857_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.916532","article-title":"Telehealth-delivered caregiver training for autism: recent innovations","volume":"13","author":"Pacione","year":"2022","journal-title":"Front Psychiatr"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00857_bib21","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1007\/s10803-023-06092-6","article-title":"Relative efficacy of self-directed and therapist-assisted telehealth models of a parent-mediated intervention for autism: examining effects on parent intervention fidelity, well-being, and program engagement","volume":"54","author":"Ingersoll","year":"2024","journal-title":"J Autism Dev Disord [Internet]"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib22","first-page":"207","article-title":"Adaptation of the research unit on behavioral interventions caregiver training program for remote group delivery: preliminary analysis of clinical outcomes","volume":"23","author":"Jimenez-Gomez","year":"2023","journal-title":"Behav Anal: Research and Practice"},{"key":"10.1016\/j.neurot.2026.e00857_bib23","article-title":"Community-based parent-training for disruptive behaviors in children with ASD using synchronous telehealth services: a pilot study","volume":"88","author":"Shanok","year":"2021","journal-title":"Res Autism Spectr Disord [Internet]"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s11689-021-09410-0","article-title":"Feasibility of delivering parent-implemented NDBI interventions in low-resource regions: a pilot randomized controlled study","volume":"14","author":"Rogers","year":"2022","journal-title":"J Neurodev Disord"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00857_bib25","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/jcpp.12161","article-title":"Randomized controlled effectiveness trial of executive function intervention for children on the autism spectrum","volume":"55","author":"Kenworthy","year":"2014","journal-title":"J Child Psychol Psychiatry [Internet]"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib26","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1177\/13623613221111212","article-title":"Leveraging technology to make parent training more accessible: randomized trial of in-person versus online executive function training for parents of autistic children","volume":"27","author":"Kenworthy","year":"2023","journal-title":"Autism"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00857_bib27","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s10803-024-06365-8","article-title":"Randomized feasibility pilot of an executive functioning intervention adapted for children's mental health settings","volume":"55","author":"Dickson","year":"2025","journal-title":"J Autism Dev Disord [Internet]"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib28","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s12310-024-09661-x","article-title":"Development of a high school-based executive function intervention for transition-age autistic youth: leveraging multi-level community partnerships","volume":"16","author":"Pugliese","year":"2024","journal-title":"School Ment Health"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00857_bib29","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1001\/jamapsychiatry.2019.4160","article-title":"Cognitive behavioral treatments for anxiety in children with autism spectrum disorder: a randomized clinical trial","volume":"77","author":"Wood","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00857_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/13591045251314906","article-title":"A cognitive help or hindrance? A systematic review of cognitive behavioural therapy to treat anxiety in young people with autism spectrum disorder","volume":"30","author":"Roberts","year":"2025","journal-title":"Clin Child Psychol Psychiatry [Internet]"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00857_bib31","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/aur.2808","article-title":"Associations between co-occurring conditions and age of autism diagnosis: implications for mental health training and adult autism research","volume":"15","author":"Jadav","year":"2022","journal-title":"Autism Res [Internet]"},{"key":"10.1016\/j.neurot.2026.e00857_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.112922","article-title":"Prevalence of comorbid psychiatric disorders among people with autism spectrum disorder: an umbrella review of systematic reviews and meta-analyses","volume":"287","author":"Hossain","year":"2020","journal-title":"Psychiatry Res"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/09540261.2018.1450229","article-title":"Co-occurring psychiatric conditions in autism spectrum disorder","volume":"30","author":"Rosen","year":"2018","journal-title":"Int Rev Psychiatr"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00857_bib34","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-049880","article-title":"Cognitive behavioral therapy for autism spectrum disorders: a systematic review","volume":"147","author":"Wang","year":"2021","journal-title":"Pediatrics"},{"key":"10.1016\/j.neurot.2026.e00857_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/423905","article-title":"Facing your fears in adolescence: cognitive-behavioral therapy for high-functioning autism spectrum disorders and anxiety","volume":"2012","author":"Reaven","year":"2012","journal-title":"Autism Res Treat"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib36","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-023-05441-0","article-title":"A cluster randomized controlled trial comparing the effectiveness of two school-based interventions for autistic youth with anxiety","volume":"24","author":"Pickard","year":"2024","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib37","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/jar.12854","article-title":"Group cognitive behavioural treatment for anxiety in autistic adolescents with intellectual disability: a pilot and feasibility study","volume":"34","author":"Blakeley-Smith","year":"2021","journal-title":"J Appl Res Intellect Disabil"},{"key":"10.1016\/j.neurot.2026.e00857_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1079471","article-title":"The efficacy of mindfulness-based therapy for anxiety, social skills, and aggressive behaviors in children and young people with autism spectrum disorder: a systematic review","volume":"14","author":"Loftus","year":"2023","journal-title":"Front Psychiatr"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00857_bib39","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1177\/1362361320974841","article-title":"Evaluating the effects of a yoga-based program integrated with third-wave cognitive behavioral therapy components on self-regulation in children on the autism spectrum: a pilot randomized controlled trial","volume":"25","author":"Tanksale","year":"2021","journal-title":"Autism"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00857_bib40","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1177\/1362361318810709","article-title":"Improving emotion regulation ability in autism: the emotional awareness and skills enhancement (EASE) program","volume":"23","author":"Conner","year":"2019","journal-title":"Autism [Internet]"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00857_bib41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1176\/appi.psychotherapy.2015.69.2.97","article-title":"The course and evolution of dialectical behavior therapy","volume":"69","author":"Linehan","year":"2015","journal-title":"Am J Psychother"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12888-020-02531-1","article-title":"The effect of dialectical behaviour therapy in autism spectrum patients with suicidality and\/or self-destructive behaviour (DIASS): study protocol for a multicentre randomised controlled trial","volume":"20","author":"Huntjens","year":"2020","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00857_bib43","first-page":"1","article-title":"Dialectical behaviour therapy to treat emotion dysregulation in autistic adults without intellectual disability: a randomised controlled trial","author":"Bemmouna","year":"2025","journal-title":"Psychother Psychosom"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/aut.2022.0011","article-title":"Leveling up dialectical behavior therapy for autistic individuals with emotion dysregulation: clinical and personal insights","volume":"6","author":"Keenan","year":"2024","journal-title":"Autism Adulthood [Internet]"},{"key":"10.1016\/j.neurot.2026.e00857_bib45","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3389\/fpsyg.2018.00923","article-title":"The use of eye-movement desensitization reprocessing (EMDR) therapy in treating post-traumatic stress Disorder-A systematic narrative review","volume":"9","author":"Wilson","year":"2018","journal-title":"Front Psychol [Internet]"},{"key":"10.1016\/j.neurot.2026.e00857_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.981975","article-title":"Eye movement desensitization and reprocessing in adolescents with autism; efficacy on ASD symptoms and stress","volume":"14","author":"Leuning","year":"2023","journal-title":"Front Psychiatr"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/13623613221080254","article-title":"Using EMDR with autistic individuals: a Delphi survey with EMDR therapists","volume":"27","author":"Fisher","year":"2023","journal-title":"Autism"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00857_bib48","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40653-019-00253-5","article-title":"Trauma and autism spectrum disorder: review, proposed treatment adaptations and future directions","volume":"12","author":"Peterson","year":"2019","journal-title":"J Child Adolesc Trauma [Internet]"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00857_bib49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/jcpp.13534","article-title":"Annual research review: shifting from \u201cnormal science\u201d to neurodiversity in autism science","volume":"63","author":"Pellicano","year":"2022","journal-title":"JCPP (J Child Psychol Psychiatry)"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00857_bib50","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2021.3982","article-title":"Behavioral intervention for social challenges in children and adolescents","volume":"175","author":"Darling","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00857_bib51","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1007\/s00787-025-02697-7","article-title":"Effects of social skills training on social responsiveness of people with autism spectrum disorder: a systematic review with meta-analysis","volume":"34","author":"Anchieta","year":"2025","journal-title":"Eur Child Adolesc Psychiatr"},{"key":"10.1016\/j.neurot.2026.e00857_bib52","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cpr.2017.01.006","article-title":"Efficacy of group social skills interventions for youth with autism spectrum disorder: a systematic review and meta-analysis","volume":"52","author":"Gates","year":"2017","journal-title":"Clin Psychol Rev"},{"key":"10.1016\/j.neurot.2026.e00857_bib53","series-title":"Neurodiversity: on the neurological underpinnings of geekdom","author":"Blume","year":"1998"},{"key":"10.1016\/j.neurot.2026.e00857_bib54","series-title":"Neurodiversity : the birth of an idea","author":"Singer","year":"2017"},{"key":"10.1016\/j.neurot.2026.e00857_bib55","article-title":"A systematic review of predictors of suicidal thoughts and behaviors among autistic adults: making the case for the role of social connection as a protective factor","volume":"99","author":"Mournet","year":"2023","journal-title":"Clin Psychol Rev [Internet]"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00857_bib56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/2150137816668561","article-title":"The effects of a romantic relationship treatment option for adults with autism spectrum disorder","volume":"7","author":"Cunningham","year":"2016","journal-title":"Counseling Outcome Research and Evaluation [Internet]"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00857_bib57","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1007\/s10803-023-05921-y","article-title":"Fostering friendship and dating skills among adults on the autism spectrum: a randomized controlled trial of the Polish version of the PEERS(R) for young adults curriculum","volume":"54","author":"Platos","year":"2024","journal-title":"J Autism Dev Disord [Internet]"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00857_bib58","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1007\/s10803-020-04482-8","article-title":"Brief report: a job-based social skills program (JOBSS) for adults with autism spectrum disorder: a pilot randomized controlled trial","volume":"50","author":"Gorenstein","year":"2020","journal-title":"J Autism Dev Disord"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00857_bib59","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1007\/s10803-017-3421-9","article-title":"A pilot randomized controlled trial of the ACCESS program: a group intervention to improve social, adaptive functioning, stress coping, and self-determination outcomes in young adults with autism spectrum disorder","volume":"48","author":"Oswald","year":"2018","journal-title":"J Autism Dev Disord [Internet]"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00857_bib60","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1007\/s10803-021-05058-w","article-title":"A systematic review and meta-analysis of social skills training for adults with autism spectrum disorder","volume":"52","author":"Dubreucq","year":"2022","journal-title":"J Autism Dev Disord [Internet]"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00857_bib61","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/13623613241275260","article-title":"A critical hit: dungeons and dragons as a buff for autistic people","volume":"29","author":"Atherton","year":"2025","journal-title":"Autism"},{"key":"10.1016\/j.neurot.2026.e00857_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ridd.2024.104771","article-title":"Effect of immersive virtual reality-based training on cognitive, social, and emotional skills in children and adolescents with autism spectrum disorder: a meta-analysis of randomized controlled trials","volume":"151","author":"Mittal","year":"2024","journal-title":"Res Dev Disabil"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00857_bib63","article-title":"Virtual reality technology as an educational and intervention tool for children with autism spectrum disorder: current perspectives and future directions","volume":"12","author":"Zhang","year":"2022","journal-title":"Behav Sci (Basel) [Internet]"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00857_bib64","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1034\/j.1601-183X.2003.00037.x","article-title":"Model of autism: increased ratio of excitation\/inhibition in key neural systems","volume":"2","author":"Rubenstein","year":"2003","journal-title":"Genes Brain Behav [Internet]"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00857_bib65","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1469-7610.1997.tb01697.x","article-title":"Plasma beta-endorphin, adrenocorticotropin hormone, and cortisol in autism","volume":"38","author":"Tordjman","year":"1997","journal-title":"JCPP (J Child Psychol Psychiatry)"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00857_bib66","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1002\/aur.2820","article-title":"Measures of tonic and phasic activity of the locus coeruleus-norepinephrine system in children with autism spectrum disorder: an event-related potential and pupillometry study","volume":"15","author":"Kim","year":"2022","journal-title":"Autism Res [Internet]"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00857_bib67","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.1977.01770170063005","article-title":"Increased norepinephrine levels and decreased dopamine-beta-hydroxylase activity in primary autism","volume":"34","author":"Lake","year":"1977","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib68","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/syn.890060309","article-title":"Autism: review of neurochemical investigation","volume":"6","author":"Cook","year":"1990","journal-title":"Synapse"},{"key":"10.1016\/j.neurot.2026.e00857_bib69","article-title":"Stress system activation in children and adolescents with autism spectrum disorder","volume":"15","author":"Makris","year":"2021","journal-title":"Front Neurosci"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00857_bib70","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/ejn.13795","article-title":"The locus coeruleus-norepinephrine system as pacemaker of attention - a developmental mechanism of derailed attentional function in autism spectrum disorder","volume":"47","author":"Bast","year":"2018","journal-title":"Eur J Neurosci [Internet]"},{"key":"10.1016\/j.neurot.2026.e00857_bib71","article-title":"Catecholaminergic and cholinergic neuromodulation in autism spectrum disorder: a comparison to attention-deficit hyperactivity disorder","volume":"16","author":"Koevoet","year":"2022","journal-title":"Front Neurosci [Internet]"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00857_bib72","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/jcpp.13305","article-title":"Practitioner review: pharmacological treatment of attention-deficit\/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis","volume":"62","author":"Rodrigues","year":"2021","journal-title":"JCPP (J Child Psychol Psychiatry)"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00857_bib73","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jaac.2015.08.013","article-title":"Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-Deficit\/Hyperactivity disorder","volume":"54","author":"Handen","year":"2015","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00857_bib74","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1176\/appi.ajp.2015.15010055","article-title":"Extended-release guanfacine for hyperactivity in children with autism spectrum disorder","volume":"172","author":"Scahill","year":"2015","journal-title":"Am J Psychiatr"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00857_bib75","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1038\/s41386-018-0039-3","article-title":"A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures","volume":"43","author":"Politte","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00857_bib76","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/JCP.0000000000001175","article-title":"The safety and effectiveness of high-dose propranolol as a treatment for challenging behaviors in individuals with autism spectrum disorders","volume":"40","author":"London","year":"2020","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00857_bib77","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/JCP.0000000000001895","article-title":"High-dose propranolol for severe and chronic aggression in autism spectrum disorder: a pilot, double-blind, placebo-controlled, randomized crossover study","volume":"44","author":"London","year":"2024","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00857_bib78","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11682-010-9098-8","article-title":"Effect of propranolol on functional connectivity in autism spectrum disorder--a pilot study","volume":"4","author":"Narayanan","year":"2010","journal-title":"Brain Imaging Behav"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00857_bib79","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/13803395.2014.904844","article-title":"Effect of propranolol on facial scanning in autism spectrum disorder: a preliminary investigation","volume":"36","author":"Zamzow","year":"2014","journal-title":"J Clin Exp Neuropsychol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00857_bib80","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00213-015-4199-0","article-title":"Effects of propranolol on conversational reciprocity in autism spectrum disorder: a pilot, double-blind, single-dose psychopharmacological challenge study","volume":"233","author":"Zamzow","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neurot.2026.e00857_bib81","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neuroscience.2015.11.010","article-title":"The serotonin system in autism spectrum disorder: from biomarker to animal models","volume":"321","author":"Muller","year":"2016","journal-title":"Neuroscience"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00857_bib82","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jaac.2012.04.010","article-title":"Examining autism spectrum disorders by biomarkers: example from the oxytocin and serotonin systems","volume":"51","author":"Hammock","year":"2012","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/revneuro-2023-0055","article-title":"The brain serotonin system in autism","volume":"35","author":"Rodnyy","year":"2024","journal-title":"Rev Neurosci"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00857_bib84","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1007\/s10803-019-03989-z","article-title":"Whole blood serotonin levels and platelet 5-HT2A binding in autism spectrum disorder","volume":"49","author":"Aaron","year":"2019","journal-title":"J Autism Dev Disord"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00857_bib85","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/0006-3223(93)90011-2","article-title":"Acute tryptophan depletion in autistic disorder: a controlled case study","volume":"33","author":"McDougle","year":"1993","journal-title":"Biol Psychiatry"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00857_bib86","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archgenpsychiatry.2009.30","article-title":"Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism","volume":"66","author":"King","year":"2009","journal-title":"Arch Gen Psychiatry"},{"issue":"16","key":"10.1016\/j.neurot.2026.e00857_bib87","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.2019.14685","article-title":"Effect of fluoxetine on obsessive-compulsive behaviors in children and adolescents with autism spectrum disorders: a randomized clinical trial","volume":"322","author":"Reddihough","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib88","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1176\/appi.ajp.2011.10050764","article-title":"A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders","volume":"169","author":"Hollander","year":"2012","journal-title":"Am J Psychiatr"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00857_bib89","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF01531306","article-title":"The effects of haloperidol on learning and behavior in autistic children","volume":"12","author":"Campbell","year":"1982","journal-title":"J Autism Dev Disord"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00857_bib90","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","article-title":"Reduction in social anxiety after MDMA-Assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study","volume":"235","author":"Danforth","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"issue":"7720","key":"10.1016\/j.neurot.2026.e00857_bib91","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-018-0416-4","article-title":"5-HT release in nucleus accumbens rescues social deficits in mouse autism model","volume":"560","author":"Walsh","year":"2018","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00857_bib92","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41386-021-01091-6","article-title":"Systemic enhancement of serotonin signaling reverses social deficits in multiple mouse models for ASD","volume":"46","author":"Walsh","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"20","key":"10.1016\/j.neurot.2026.e00857_bib93","doi-asserted-by":"crossref","first-page":"8278","DOI":"10.1523\/JNEUROSCI.21-20-08278.2001","article-title":"Oxytocin in the medial amygdala is essential for social recognition in the mouse","volume":"21","author":"Ferguson","year":"2001","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib94","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1755-5949.2008.00051.x","article-title":"Oxytocin levels in social anxiety disorder","volume":"14","author":"Hoge","year":"2008","journal-title":"CNS Neurosci Ther"},{"issue":"49","key":"10.1016\/j.neurot.2026.e00857_bib95","doi-asserted-by":"crossref","first-page":"11489","DOI":"10.1523\/JNEUROSCI.3984-05.2005","article-title":"Oxytocin modulates neural circuitry for social cognition and fear in humans","volume":"25","author":"Kirsch","year":"2005","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib96","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.psyneuen.2009.06.016","article-title":"Effects of intranasal oxytocin on emotional face processing in women","volume":"35","author":"Domes","year":"2010","journal-title":"Psychoneuroendocrinology"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00857_bib97","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.biopsych.2006.07.015","article-title":"Oxytocin improves \u201cmind-reading\u201d in humans","volume":"61","author":"Domes","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00857_bib98","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.biopsych.2006.05.030","article-title":"Oxytocin increases retention of social cognition in autism","volume":"61","author":"Hollander","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00857_bib99","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.biopsych.2009.09.020","article-title":"Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders","volume":"67","author":"Guastella","year":"2010","journal-title":"Biol Psychiatry"},{"issue":"30","key":"10.1016\/j.neurot.2026.e00857_bib100","doi-asserted-by":"crossref","first-page":"8119","DOI":"10.1073\/pnas.1705521114","article-title":"Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism","volume":"114","author":"Parker","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00857_bib101","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/mp.2015.162","article-title":"The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial","volume":"21","author":"Yatawara","year":"2016","journal-title":"Mol Psychiatr"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00857_bib102","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41380-018-0097-2","article-title":"Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial","volume":"25","author":"Yamasue","year":"2020","journal-title":"Mol Psychiatr"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00857_bib103","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/jcpp.12305","article-title":"The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial","volume":"56","author":"Guastella","year":"2015","journal-title":"JCPP (J Child Psychol Psychiatry)"},{"issue":"16","key":"10.1016\/j.neurot.2026.e00857_bib104","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJMoa2103583","article-title":"Intranasal oxytocin in children and adolescents with autism spectrum disorder","volume":"385","author":"Sikich","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00857_bib105","first-page":"421","article-title":"[Oxytocin in the treatment of the social deficits associated to autism spectrum disorders]","volume":"61","author":"Cachafeiro-Espino","year":"2015","journal-title":"Rev Neurol"},{"key":"10.1016\/j.neurot.2026.e00857_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1127792","article-title":"Modulation of social behavior by distinct vasopressin sources","volume":"14","author":"Rigney","year":"2023","journal-title":"Front Endocrinol"},{"issue":"20","key":"10.1016\/j.neurot.2026.e00857_bib107","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1073\/pnas.0600406103","article-title":"Sex-specific influences of vasopressin on human social communication","volume":"103","author":"Thompson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00857_bib108","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1006\/hbeh.2001.1655","article-title":"Central vasopressin administration regulates the onset of facultative paternal behavior in microtus pennsylvanicus (meadow voles)","volume":"39","author":"Parker","year":"2001","journal-title":"Horm Behav"},{"issue":"439","key":"10.1016\/j.neurot.2026.e00857_bib109","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam9100","article-title":"Arginine vasopressin in cerebrospinal fluid is a marker of sociality in nonhuman primates","volume":"10","author":"Parker","year":"2018","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00857_bib110","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ana.25314","article-title":"Cerebrospinal fluid vasopressin and symptom severity in children with autism","volume":"84","author":"Oztan","year":"2018","journal-title":"Ann Neurol"},{"issue":"491","key":"10.1016\/j.neurot.2026.e00857_bib111","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7356","article-title":"A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism","volume":"11","author":"Parker","year":"2019","journal-title":"Sci Transl Med"},{"issue":"491","key":"10.1016\/j.neurot.2026.e00857_bib112","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat7838","article-title":"A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder","volume":"11","author":"Bolognani","year":"2019","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib113","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2215-0366(21)00429-6","article-title":"Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial","volume":"9","author":"Jacob","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00857_bib114","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamapsychiatry.2022.1717","article-title":"Balovaptan vs placebo for social communication in childhood autism spectrum disorder","volume":"79","author":"Hollander","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13229-022-00505-6","article-title":"Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program","volume":"13","author":"Jacob","year":"2022","journal-title":"Mol Autism"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00857_bib116","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41380-019-0426-0","article-title":"Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders","volume":"24","author":"Sohal","year":"2019","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.neurot.2026.e00857_bib117","first-page":"13","article-title":"Can bumetanide be a miraculous medicine for autism spectrum disorder: meta-analysis evidence from randomized controlled trials","volume":"114","author":"Xiao","year":"2024","journal-title":"Res Autism Spectr Disord [Internet]"},{"key":"10.1016\/j.neurot.2026.e00857_bib118","article-title":"The pediatric psychopharmacology of autism spectrum disorder: a systematic review - part II: the future","volume":"136","author":"Persico","year":"2024","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry [Internet]"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00857_bib119","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/aur.3005","article-title":"Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: results from two randomized phase III studies","volume":"16","author":"Fuentes","year":"2023","journal-title":"Autism Res"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib120","first-page":"251","article-title":"Prediction of behavioral improvement through resting-state electroencephalography and clinical severity in a randomized controlled trial testing bumetanide in autism spectrum disorder","volume":"8","author":"Juarez-Martinez","year":"2023","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"15","key":"10.1016\/j.neurot.2026.e00857_bib121","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.scib.2021.01.008","article-title":"Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dai","year":"2021","journal-title":"Sci Bull"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib122","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41398-020-0692-2","article-title":"Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA\/glutamate ratios","volume":"10","author":"Zhang","year":"2020","journal-title":"Transl Psychiatry"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib123","article-title":"The GABA polarity shift and bumetanide treatment: making sense requires unbiased and undogmatic analysis","volume":"11","author":"Ben-Ari","year":"2022","journal-title":"Cells [Internet]"},{"key":"10.1016\/j.neurot.2026.e00857_bib124","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fncel.2015.00034","article-title":"Update on the implication of potassium channels in autism: K(+) channelautism spectrum disorder","volume":"9","author":"Guglielmi","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.neurot.2026.e00857_bib125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s11689-016-9181-6","article-title":"Arbaclofen in fragile X syndrome: results of phase 3 trials","volume":"9","author":"Berry-Kravis","year":"2017","journal-title":"J Neurodev Disord [Internet]"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00857_bib126","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/npp.2016.237","article-title":"Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial","volume":"42","author":"Veenstra-VanderWeele","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neurot.2026.e00857_bib127","series-title":"Arbaclofen trial for autistic youth: pooled analysis of EU and Canadian trials. Presented at: INSAR 2024 Annual Meeting May; Oral Presentation no: 305.001","author":"Pmacsjcamccer","year":"2024"},{"key":"10.1016\/j.neurot.2026.e00857_bib128","volume":"2025","author":"Guglielmi","year":"2023"},{"issue":"7363","key":"10.1016\/j.neurot.2026.e00857_bib129","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nature10360","article-title":"Neocortical excitation\/inhibition balance in information processing and social dysfunction","volume":"477","author":"Yizhar","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00857_bib130","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.neuron.2018.12.026","article-title":"Increased excitation-inhibition ratio stabilizes synapse and circuit excitability in four autism mouse models","volume":"101","author":"Antoine","year":"2019","journal-title":"Neuron"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00857_bib131","first-page":"CD013845","article-title":"Memantine for autism spectrum disorder","volume":"8","author":"Brignell","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00857_bib132","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1177\/1362361318824103","article-title":"Efficacy and safety of memantine in children with autism spectrum disorder: results from three phase 2 multicenter studies","volume":"23","author":"Hardan","year":"2019","journal-title":"Autism"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib133","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/JCP.0000000000000499","article-title":"A prospective open-label trial of memantine hydrochloride for the treatment of social deficits in intellectually capable adults with autism spectrum disorder","volume":"36","author":"Joshi","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.neurot.2026.e00857_bib134","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1395867","article-title":"NMDA antagonist agents for the treatment of symptoms in autism spectrum disorder: a systematic review and meta-analysis","volume":"15","author":"Dessus-Gilbert","year":"2024","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00857_bib135","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1007\/s10803-020-04542-z","article-title":"Brief report: intranasal ketamine in adolescents and young adults with autism spectrum disorder-initial results of a randomized, controlled, crossover, pilot Study","volume":"51","author":"Wink","year":"2021","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.neurot.2026.e00857_bib136","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/1471-244X-13-196","article-title":"A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders","volume":"13","author":"Ghanizadeh","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib137","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/WNF.0000000000000063","article-title":"N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety","volume":"38","author":"Nikoo","year":"2015","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.neurot.2026.e00857_bib138","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13229-016-0088-6","article-title":"A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder","volume":"7","author":"Wink","year":"2016","journal-title":"Mol Autism"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib139","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0004867416652735","article-title":"A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder","volume":"51","author":"Dean","year":"2017","journal-title":"Aust N Z J Psychiatr"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00857_bib140","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrn1247","article-title":"The molecular logic of endocannabinoid signalling","volume":"4","author":"Piomelli","year":"2003","journal-title":"Nat Rev Neurosci"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00857_bib141","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd1495","article-title":"The endocannabinoid system and its therapeutic exploitation","volume":"3","author":"Marzo","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib142","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030833","article-title":"Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system","volume":"19","author":"Zou","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2026.e00857_bib143","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1017\/S1462399409000957","article-title":"Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation","volume":"11","author":"Cabral","year":"2009","journal-title":"Expet Rev Mol Med"},{"key":"10.1016\/j.neurot.2026.e00857_bib144","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13229-019-0256-6","article-title":"Lower circulating endocannabinoid levels in children with autism spectrum disorder","volume":"10","author":"Aran","year":"2019","journal-title":"Mol Autism"},{"key":"10.1016\/j.neurot.2026.e00857_bib145","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13229-018-0203-y","article-title":"Plasma anandamide concentrations are lower in children with autism spectrum disorder","volume":"9","author":"Karhson","year":"2018","journal-title":"Mol Autism"},{"issue":"21","key":"10.1016\/j.neurot.2026.e00857_bib146","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib147","article-title":"Efficacy and safety of cannabinoids for autism spectrum disorder: an updated systematic review","volume":"17","author":"Pereira","year":"2025","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00857_bib148","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1007\/s11606-020-06504-8","article-title":"Cannabidiol interactions with medications, illicit substances, and alcohol: a comprehensive review","volume":"36","author":"Balachandran","year":"2021","journal-title":"J Gen Intern Med"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib149","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cpt.2973","article-title":"Evaluation of cytochrome P450-Mediated cannabinoid-drug interactions in healthy adult participants","volume":"114","author":"Bansal","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.neurot.2026.e00857_bib150","doi-asserted-by":"crossref","DOI":"10.1007\/s10803-025-06884-y","article-title":"Cannabidiol (CBD) treatment for severe problem behaviors in autistic boys: a randomized clinical trial","author":"Trauner","year":"2025","journal-title":"J Autism Dev Disord"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00857_bib151","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41386-024-02001-2","article-title":"Efficacy and safety of JNJ-42165279, a fatty acid amide hydrolase inhibitor, in adolescents and adults with autism spectrum disorder: a randomized, phase 2, placebo-controlled study","volume":"50","author":"Klein","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neurot.2026.e00857_bib152","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.mito.2013.08.006","article-title":"Metabolic features of the cell danger response","volume":"16","author":"Naviaux","year":"2014","journal-title":"Mitochondrion"},{"key":"10.1016\/j.neurot.2026.e00857_bib153","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mito.2017.12.007","article-title":"Antipurinergic therapy for autism\u2014An in-depth review","volume":"43","author":"Naviaux","year":"2018","journal-title":"Mitochondrion"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2040-2392-6-1","article-title":"Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model","volume":"6","author":"Naviaux","year":"2015","journal-title":"Mol Autism"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00857_bib155","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1038\/tp.2014.33","article-title":"Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy","volume":"4","author":"Naviaux","year":"2014","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.neurot.2026.e00857_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107930","article-title":"Effects of single-dose antipurinergic therapy on behavioral and molecular alterations in the valproic acid-induced animal model of autism","volume":"167","author":"Hirsch","year":"2020","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00857_bib157","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/acn3.424","article-title":"Low-dose suramin in autism spectrum disorder: a small, phase I\/II, randomized clinical trial","volume":"4","author":"Naviaux","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00857_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaac.2021.09.410","article-title":"Suramin intravenous INFUSION for treating BOYS with autism spectrum disorder: results of a 14-WEEK, randomized, double-blind, placebo-controlled, multidose, phase 2 study","volume":"60","author":"Hough","year":"2021","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib159","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12991-023-00477-8","article-title":"Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder","volume":"22","author":"Hough","year":"2023","journal-title":"Ann Gen Psychiatr"},{"key":"10.1016\/j.neurot.2026.e00857_bib160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.euroneuro.2021.05.010","article-title":"Drug development for Autism spectrum disorder (ASD): progress, challenges, and future directions","volume":"48","author":"McCracken","year":"2021","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.neurot.2026.e00857_bib161","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13229-017-0146-8","article-title":"The EU-AIMS longitudinal European Autism project (LEAP): design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders","volume":"8","author":"Loth","year":"2017","journal-title":"Mol Autism"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib162","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1176\/appi.ajp.21050485","article-title":"The autism biomarkers consortium for clinical trials: initial evaluation of a battery of candidate EEG biomarkers","volume":"180","author":"Webb","year":"2023","journal-title":"Am J Psychiatr"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00857_bib163","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/JCP.0000000000000536","article-title":"Derisking psychiatric drug development: the nimh's fast fail program, A novel precompetitive model","volume":"36","author":"Grabb","year":"2016","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib164","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13229-022-00488-4","article-title":"Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis","volume":"13","author":"Siafis","year":"2022","journal-title":"Mol Autism"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00857_bib165","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1001\/jamapediatrics.2013.2698","article-title":"Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial","volume":"167","author":"King","year":"2013","journal-title":"JAMA Pediatr"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00857_bib166","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s41386-023-01573-9","article-title":"Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder","volume":"48","author":"Tobe","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib167","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/bul0000215","article-title":"Project AIM: autism intervention meta-analysis for studies of young children","volume":"146","author":"Sandbank","year":"2020","journal-title":"Psychol Bull"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/bul0000215","article-title":"Project AIM: autism intervention meta-analysis for studies of young children","volume":"146","author":"Sandbank","year":"2020","journal-title":"Psychol Bull"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00857_bib169","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269800","article-title":"The use of social robots with children and young people on the autism spectrum: a systematic review and meta-analysis","volume":"17","author":"Kouroupa","year":"2022","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00857_bib170","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1007\/s10803-020-04778-9","article-title":"Digital interventions for autism spectrum disorder: a meta-analysis","volume":"51","author":"Sandgreen","year":"2021","journal-title":"J Autism Dev Disord"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00857_bib171","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00787-021-01804-8","article-title":"Pivotal response treatment with and without robot-assistance for children with autism: a randomized controlled trial","volume":"31","author":"van den Berk-Smeekens","year":"2022","journal-title":"Eur Child Adolesc Psychiatr"},{"key":"10.1016\/j.neurot.2026.e00857_bib172","doi-asserted-by":"crossref","first-page":"109466","DOI":"10.1109\/ACCESS.2020.3001365","article-title":"A preliminary study on effectiveness of a standardized multi-robot therapy for improvement in collaborative multi-human interaction of children with ASD","volume":"8","author":"Ali","year":"2020","journal-title":"IEEE Access"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00857_bib173","first-page":"2943","article-title":"Applications of robotics for autism spectrum disorder: a scoping review","volume":"53","author":"Santos","year":"2023","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.neurot.2026.e00857_bib174","article-title":"Efficacy of non-wearable VR-based behavioral training for preschool children with high-functioning autism spectrum disorder: a randomized clinical trial","volume":"14","author":"Chu","year":"2023","journal-title":"Front Psychiatr"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00857_bib175","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1001\/jamapediatrics.2019.0285","article-title":"Effect of wearable digital intervention for improving socialization in children with autism spectrum disorder: a randomized clinical trial","volume":"173","author":"Voss","year":"2019","journal-title":"JAMA Pediatr"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib176","first-page":"88","article-title":"Effectiveness of IMPUTE ADT-1 mobile application in children with autism spectrum disorder: an interim analysis of an ongoing randomized controlled trial","volume":"15","author":"Panda","year":"2024","journal-title":"J Neurosci Rural Pract"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib177","first-page":"254","article-title":"Social skills training for autism spectrum disorder: a meta-analysis of in-person and technological interventions","volume":"51","author":"Soares","year":"2021","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.neurot.2026.e00857_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108564","article-title":"Retracing our steps: a review on autism research in children, its limitation and impending pharmacological interventions","volume":"253","author":"Salloum-Asfar","year":"2024","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib179","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/aur.3041","article-title":"The use of noninvasive brain stimulation techniques in autism spectrum disorder","volume":"17","author":"Oberman","year":"2024","journal-title":"Autism Res"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00857_bib180","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.biopsych.2025.01.002","article-title":"Personalized Theta burst stimulation enhances social skills in young minimally verbal children with autism: a double-blind randomized controlled trial","volume":"97","author":"Xiao","year":"2025","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib181","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/aur.2266","article-title":"Treatment of adults with autism and major depressive disorder using transcranial magnetic stimulation: an open label pilot study","volume":"13","author":"Gwynette","year":"2020","journal-title":"Autism Res"},{"key":"10.1016\/j.neurot.2026.e00857_bib182","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.875591","article-title":"Prevalence of adverse effects associated with transcranial magnetic stimulation for autism spectrum disorder: a systematic review and meta-analysis","volume":"13","author":"Huashuang","year":"2022","journal-title":"Front Psychiatr"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00857_bib183","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ner.13455","article-title":"A systematic review of the safety and tolerability of theta burst stimulation in children and adolescents","volume":"25","author":"Elmaghraby","year":"2022","journal-title":"Neuromodulation"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib184","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/WNP.0b013e318205135f","article-title":"Safety of theta burst transcranial magnetic stimulation: a systematic review of the literature","volume":"28","author":"Oberman","year":"2011","journal-title":"J Clin Neurophysiol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib185","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1007\/s10803-024-06244-2","article-title":"Accelerated Theta burst transcranial magnetic stimulation for refractory depression in autism spectrum disorder","volume":"55","author":"Blank","year":"2025","journal-title":"J Autism Dev Disord"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib186","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.brs.2020.01.007","article-title":"Treatment of executive function deficits in autism spectrum disorder with repetitive transcranial magnetic stimulation: a double-blind, sham-controlled, pilot trial","volume":"13","author":"Ameis","year":"2020","journal-title":"Brain Stimul"},{"key":"10.1016\/j.neurot.2026.e00857_bib187","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.711542","article-title":"Modulation of dorsolateral prefrontal cortex glutamate\/glutamine levels following repetitive transcranial magnetic stimulation in young adults with autism","volume":"15","author":"Moxon-Emre","year":"2021","journal-title":"Front Neurosci"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00857_bib188","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/cap.2024.0109","article-title":"Probing the neurodynamic mechanisms of cognitive flexibility in depressed individuals with autism spectrum disorder","volume":"35","author":"Elmaghraby","year":"2025","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00857_bib189","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/aur.2954","article-title":"A lack of efficacy of continuous theta burst stimulation over the left dorsolateral prefrontal cortex in autism: a double blind randomized sham-controlled trial","volume":"16","author":"Ni","year":"2023","journal-title":"Autism Res"},{"key":"10.1016\/j.neurot.2026.e00857_bib190","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2024.105807","article-title":"A network meta-analysis of non-invasive brain stimulation interventions for autism spectrum disorder: evidence from randomized controlled trials","volume":"164","author":"Chen","year":"2024","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.neurot.2026.e00857_bib191","doi-asserted-by":"crossref","DOI":"10.1016\/j.spen.2020.100832","article-title":"Transcranial magnetic stimulation in autism spectrum disorders: neuropathological underpinnings and clinical correlations","volume":"35","author":"Casanova","year":"2020","journal-title":"Semin Pediatr Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00857_bib192","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00460","article-title":"Multisession tDCS combined with intrastimulation training improves emotion recognition in adolescents with autism spectrum disorder","volume":"21","author":"Prillinger","year":"2024","journal-title":"Neurotherapeutics"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00857_bib193","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.biopsych.2024.12.001","article-title":"Deep brain stimulation of the nucleus accumbens for severe self-injurious behavior in children: a phase I pilot trial","volume":"97","author":"Gorodetsky","year":"2025","journal-title":"Biol Psychiatry"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00857_bib194","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3171\/2010.3.PEDS09153","article-title":"Vagus nerve stimulation therapy in patients with autism spectrum disorder and intractable epilepsy: results from the vagus nerve stimulation therapy patient outcome registry","volume":"5","author":"Levy","year":"2010","journal-title":"J Neurosurg Pediatr"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00857_bib195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009477","article-title":"The meaning of significant mean group differences for biomarker discovery","volume":"17","author":"Loth","year":"2021","journal-title":"PLoS Comput Biol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00857_bib196","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/WCO.0000000000000542","article-title":"Clinical trials in autism spectrum disorder: evidence, challenges and future directions","volume":"31","author":"Anagnostou","year":"2018","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib197","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-019-0138-4","article-title":"Autism spectrum disorder","volume":"6","author":"Lord","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.neurot.2026.e00857_bib198","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data","volume":"39","author":"Erdos","year":"2022","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00857_bib199","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.yebeh.2011.04.060","article-title":"Autism in Dravet syndrome: prevalence, features, and relationship to the clinical characteristics of epilepsy and mental retardation","volume":"21","author":"Li","year":"2011","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00857_bib201","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1399-0004.2004.00362.x","article-title":"Autism in angelman syndrome: implications for autism research","volume":"66","author":"Peters","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.neurot.2026.e00857_bib202","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jconrel.2023.01.067","article-title":"AAV vectors applied to the treatment of CNS disorders: clinical status and challenges","volume":"355","author":"Kang","year":"2023","journal-title":"J Contr Release"},{"issue":"6701","key":"10.1016\/j.neurot.2026.e00857_bib203","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.adm8386","article-title":"An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery","volume":"384","author":"Huang","year":"2024","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.neurot.2026.e00857_bib204","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with Duchenne's muscular dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00857_bib205","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cell.2024.01.042","article-title":"Past, present, and future of CRISPR genome editing technologies","volume":"187","author":"Pacesa","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib206","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41392-024-01750-2","article-title":"Precise genome-editing in human diseases: mechanisms, strategies and applications","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"issue":"18","key":"10.1016\/j.neurot.2026.e00857_bib207","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.neurot.2026.e00857_bib208","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene autotemcel for transfusion-dependent \u03b2-Thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.neurot.2026.e00857_bib209","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","article-title":"Patient-specific in vivo gene editing to treat a rare genetic disease","volume":"392","author":"Musunuru","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00857_bib210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165499","article-title":"Reactivation of FMR1 by CRISPR\/Cas9-Mediated deletion of the expanded CGG-repeat of the fragile X chromosome","volume":"11","author":"Xie","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00857_bib211","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1016\/j.cell.2023.04.035","article-title":"Site-specific R-loops induce CGG repeat contraction and fragile X gene reactivation","volume":"186","author":"Lee","year":"2023","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00857_bib212","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41431-020-0624-x","article-title":"High rate of HDR in gene editing of p.(Thr158Met) MECP2 mutational hotspot","volume":"28","author":"Croci","year":"2020","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00857_bib213","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142574","article-title":"CRISPR\/Cas9 directed to the Ube3a antisense transcript improves angelman syndrome phenotype in mice","volume":"131","author":"Schmid","year":"2021","journal-title":"J Clin Investig"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00857_bib214","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/epi.18209","article-title":"The epilepsy\u2013autism phenotype associated with developmental and epileptic encephalopathies: new mechanism-based therapeutic options","volume":"66","author":"Specchio","year":"2025","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib215","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s11689-023-09511-y","article-title":"Endophenotype trait domains for advancing gene discovery in autism spectrum disorder","volume":"15","author":"Mosconi","year":"2023","journal-title":"J Neurodev Disord"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00857_bib216","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1089\/aut.2023.0030","article-title":"Moving from disorder to difference: a systematic review of recent language use in autism research","volume":"6","author":"Bottini","year":"2024","journal-title":"Autism Adulthood"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00857_bib217","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/aur.2898","article-title":"Autism severity and its relationship to disability","volume":"16","author":"Waizbard-Bartov","year":"2023","journal-title":"Autism Res"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00857_bib218","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12916-024-03814-0","article-title":"Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms","volume":"23","author":"Manter","year":"2025","journal-title":"BMC Med"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:08:30Z","timestamp":1772856510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926000279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":217,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1878747926000279"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00857","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapeutics in autism spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00857"}}